Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.

Ingwersen SH, Petri KC, Tandon N, Yoon KH, Chen L, Vora J, Yang W

Diabetes research and clinical practice19 Jan 2015Cited by 12 (Europe PMC)

PMID25684604DOI10.1016/j.diabres.2015.01.001PepBankPUB-25684604

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes, exposure-response analysis supported 1.2 mg as maintenance dose with the option of escalation to 1.8 mg.
In plain wordsIn Asian adults with type 2 diabetes, the analysis supported 1.2 mg as the usual dose, with a step up to 1.8 mg possible.
Peptide
Liraglutide
Outcome
Not applicableExposure-response analysis for dose selection
Study
n = 605
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Exposure-response analysis supported the use of 1.2mg as maintenance dose with the option of individual dose escalation to 1.8 mg to optimize treatment outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
An exploratory exposure-response analysis was conducted to investigate effects on glycated haemoglobin (HbA1c) and body weight.
Summary · context
Data were derived from a published 16-week, randomized, double-blind, double-dummy, active-controlled, parallel-group trial of liraglutide in China, India and South Korea.
Summary · context
The analysis utilized 2061 pharmacokinetic (PK) samples from 605 subjects exposed to liraglutide 0.6, 1.2 or 1.8 mg once daily.
Report a problemFND-2568460404
02HumanRandomized controlled trialEfficacy outcome
In Asian adults with type 2 diabetes, exposure-response relationships for HbA1c and body weight were similar to observations in global populations.
In plain wordsIn Asian adults with type 2 diabetes, the link between liraglutide levels and HbA1c and weight was similar to that seen in global populations.
Peptide
Liraglutide
Outcome
Not applicableExposure-response relationship for HbA1c and body weight
Study
n = 605
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
The exposure-response relationships for HbA1c and body weight in Asian subjects were similar to observations in global populations.
2 context sentences(design, population, supporting numbers)
Summary · context
Data were derived from a published 16-week, randomized, double-blind, double-dummy, active-controlled, parallel-group trial of liraglutide in China, India and South Korea.
Summary · context
The analysis utilized 2061 pharmacokinetic (PK) samples from 605 subjects exposed to liraglutide 0.6, 1.2 or 1.8 mg once daily.
Report a problemFND-2568460405
03HumanRandomized controlled trialPharmacokinetics
In Asian adults with type 2 diabetes, estimated liraglutide exposure (AUC) increased proportionally with dose from 0.6 to 1.8 mg.
In plain wordsIn Asian adults with type 2 diabetes, the amount of liraglutide in the body rose in step with the dose.
Peptide
Liraglutide
Outcome
IncreaseLiraglutide exposure (AUC) by dose
Study
n = 605
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.6-1.8 mg · 16 weeksAs given in this study (human).
Measurements
Dose range
0.6 to 1.8 mg
once daily
Source sentences
Summary
Estimated liraglutide exposure (area under the curve; AUC) appeared to increase proportionally with increasing liraglutide dose (0.6-1.8 mg).
2 context sentences(design, population, supporting numbers)
Summary · context
Data were derived from a published 16-week, randomized, double-blind, double-dummy, active-controlled, parallel-group trial of liraglutide in China, India and South Korea.
Summary · context
The analysis utilized 2061 pharmacokinetic (PK) samples from 605 subjects exposed to liraglutide 0.6, 1.2 or 1.8 mg once daily.
Report a problemFND-2568460401
04HumanRandomized controlled trialPharmacokinetics
In Asian adults with type 2 diabetes, body weight predicted liraglutide exposure: exposure was 32% lower at 115 kg and 54% higher at 37 kg, compared with a 67 kg reference subject.
In plain wordsIn Asian adults with type 2 diabetes, heavier people had lower liraglutide levels and lighter people had higher levels.
Peptide
Liraglutide
Outcome
MixedEffect of body weight on liraglutide exposure
Study
n = 605
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Exposure lower at maximum weight
32%
115 kg
Exposure higher at minimum weight
54%
37 kg
Source sentences
Summary
Body weight was a predictor of liraglutide exposure; compared to a reference subject of 67 kg, exposure was 32% lower for maximum (115 kg) and 54% higher for minimum (37 kg) observed body weights.
2 context sentences(design, population, supporting numbers)
Summary · context
Data were derived from a published 16-week, randomized, double-blind, double-dummy, active-controlled, parallel-group trial of liraglutide in China, India and South Korea.
Summary · context
The analysis utilized 2061 pharmacokinetic (PK) samples from 605 subjects exposed to liraglutide 0.6, 1.2 or 1.8 mg once daily.
Report a problemFND-2568460402
05HumanRandomized controlled trialPharmacokinetics
In Asian adults with type 2 diabetes, gender, age and country had no relevant effect on liraglutide exposure.
In plain wordsIn Asian adults with type 2 diabetes, gender, age and country made no relevant difference to liraglutide levels.
Peptide
Liraglutide
Outcome
No significant changeEffect of gender, age and country on liraglutide exposure
Study
n = 605
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Gender, age and country had no relevant effect on exposure.
2 context sentences(design, population, supporting numbers)
Summary · context
Data were derived from a published 16-week, randomized, double-blind, double-dummy, active-controlled, parallel-group trial of liraglutide in China, India and South Korea.
Summary · context
The analysis utilized 2061 pharmacokinetic (PK) samples from 605 subjects exposed to liraglutide 0.6, 1.2 or 1.8 mg once daily.
Report a problemFND-2568460403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00614120

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 929Jan 2008 to Feb 2009

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.